SCHIZO-CV: Prevalence of Cardiovascular Disorders in Patients Aged 40 and More With Schizophrenia

• Sponsor: Université de Reims Champagne-Ardenne (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT05174533
• Collaborator: (none)
• Enrollment: 50
• Location: 1
• Anticipated Duration (Months): 5.9
• Patients Per Site Per Month: 8.4

Study Details

Study Description

Brief Summary

Schizophrenia is a psychiatric disorder, affecting 600,000 patients in France. Patients with schizophrenia have life expectancy decrease from 10 to 20 years because of cardiovascular death. Cardiovascular risk factors are numerous: inadequate diet, smoking, alcohol consumption, diabetes, obesity. Primary prevention of cardiovascular risk in patients suffering from schizophrenia is difficult because of understaff in general practitioners and psychiatrists.

Condition or Disease	Intervention/Treatment	Phase
Schizophrenia	Other: Data collection

Detailed Description

The aim of the study is to describe prevalence of cardiovascular disorders in patients aged 40 and more with schizophrenia.

Study Design

• Study Type: Observational
• Anticipated Enrollment: 50 participants
• Observational Model: Case-Only
• Time Perspective: Prospective
• Official Title: Prevalence of Cardiovascular Disorders in Patients Aged 40 and More With Schizophrenia
• Actual Study Start Date: Jan 12, 2022
• Anticipated Primary Completion Date: May 12, 2022
• Anticipated Study Completion Date: Jul 12, 2022

Arms and Interventions

Arm	Intervention/Treatment
with schizophrenia "with schizophrenia" group : patients aged 40 and more with schizophrenia	Other: Data collection; electrocardiogram

Outcome Measures

Primary Outcome Measures

1. QRS morphology [Day 0]

   variation of QRS waves according a standard 12-lead ECG

Secondary Outcome Measures

1. cardiac rhythm [Day 0]

   cardiac rhythm disorder according a standard 12-lead ECG

Eligibility Criteria

Criteria

• Ages Eligible for Study: 40 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• male or female

• aged of 40 and more

• with schizophrenia

• agreeing to participate in the study

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Epsmd de l'Aisne	Prémontré	Grand-Est	France	02320

Sponsors and Collaborators

• Université de Reims Champagne-Ardenne

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Université de Reims Champagne-Ardenne
• ClinicalTrials.gov Identifier: NCT05174533
• Other Study ID Numbers: 2021-011-SCHIZO-CV
• First Posted: Dec 30, 2021
• Last Update Posted: Feb 1, 2022
• Last Verified: Jan 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Université de Reims Champagne-Ardenne: schizophrenia; cardiovascular disorders; prevalence
• Additional relevant MeSH terms: Cardiovascular Diseases; Schizophrenia

Study Results

No Results Posted as of Feb 1, 2022